DK1372682T3 - Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser - Google Patents
Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelserInfo
- Publication number
- DK1372682T3 DK1372682T3 DK02721413.9T DK02721413T DK1372682T3 DK 1372682 T3 DK1372682 T3 DK 1372682T3 DK 02721413 T DK02721413 T DK 02721413T DK 1372682 T3 DK1372682 T3 DK 1372682T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- fibrillogenesis
- catechins
- amyloidosis
- parkinson
- Prior art date
Links
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 title abstract 4
- 235000005487 catechin Nutrition 0.000 title abstract 4
- 230000035557 fibrillogenesis Effects 0.000 title abstract 3
- 150000001765 catechin Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000023769 AA amyloidosis Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract 2
- 102100031639 Nascent polypeptide-associated complex subunit alpha Human genes 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 229950001002 cianidanol Drugs 0.000 abstract 2
- 235000020688 green tea extract Nutrition 0.000 abstract 2
- 108010037351 nascent-polypeptide-associated complex Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940094952 green tea extract Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27686601P | 2001-03-15 | 2001-03-15 | |
| US33896901P | 2001-12-10 | 2001-12-10 | |
| PCT/US2002/007755 WO2003013442A2 (en) | 2001-03-15 | 2002-03-15 | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1372682T3 true DK1372682T3 (da) | 2012-08-20 |
Family
ID=26958170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02721413.9T DK1372682T3 (da) | 2001-03-15 | 2002-03-15 | Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1372682B1 (enExample) |
| JP (1) | JP2004537576A (enExample) |
| AT (1) | ATE555807T1 (enExample) |
| CA (1) | CA2440293C (enExample) |
| DK (1) | DK1372682T3 (enExample) |
| ES (1) | ES2387910T3 (enExample) |
| NZ (1) | NZ528321A (enExample) |
| PT (1) | PT1372682E (enExample) |
| WO (1) | WO2003013442A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514107B2 (en) | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| EP1663199B1 (en) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| EP1713457A2 (de) * | 2004-02-11 | 2006-10-25 | Max-Delbrück-Centrum Für Molekulare Medizin | Neue arzneimittel und diagnostische zusammensetzungen f r be handlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US20100040558A1 (en) * | 2005-04-26 | 2010-02-18 | University Of South Florida | Green tea polyphenol alpha secretase enhancers and methods of use |
| JP2007022946A (ja) * | 2005-07-14 | 2007-02-01 | Mitsui Norin Co Ltd | マクロファージ遊走阻止因子の酵素活性阻害剤 |
| US10004828B2 (en) | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
| JP5738755B2 (ja) * | 2008-05-09 | 2015-06-24 | アイカーン スクール オブ メディシン アット マウント シナイ | 神経変性疾患を予防および治療するための方法 |
| JP6068484B2 (ja) | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| US20180271927A1 (en) * | 2015-05-27 | 2018-09-27 | Nippon Paper Industries Co., Ltd. | Brain function-protecting agent |
| KR102441381B1 (ko) * | 2016-07-18 | 2022-09-07 | (주)아모레퍼시픽 | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물 |
| JPWO2019054461A1 (ja) * | 2017-09-15 | 2020-08-27 | 株式会社明治 | 神経機能の維持または回復用組成物 |
| CN109799352B (zh) * | 2019-01-29 | 2022-03-08 | 北京健坤禾润科技有限公司 | 化学发光试剂及其在免疫检测中应用 |
| JP2025513275A (ja) * | 2022-04-20 | 2025-04-24 | サンテック メディカル，インコーポレイティド | 中枢神経系疾患の治療方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1275905B1 (it) * | 1995-03-14 | 1997-10-24 | Indena Spa | Frazioni polifenoliche di te', loro uso e formulazioni che le contengono |
| JPH10245342A (ja) * | 1997-03-03 | 1998-09-14 | Mitsui Norin Kk | β−アミロイド蛋白の神経細胞毒性低減剤 |
| WO1998051302A1 (en) * | 1997-05-15 | 1998-11-19 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| EP1246632A4 (en) * | 1999-12-30 | 2004-08-18 | Proteotech Inc | CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER |
-
2002
- 2002-03-15 PT PT02721413T patent/PT1372682E/pt unknown
- 2002-03-15 WO PCT/US2002/007755 patent/WO2003013442A2/en not_active Ceased
- 2002-03-15 AT AT02721413T patent/ATE555807T1/de active
- 2002-03-15 ES ES02721413T patent/ES2387910T3/es not_active Expired - Lifetime
- 2002-03-15 EP EP02721413A patent/EP1372682B1/en not_active Expired - Lifetime
- 2002-03-15 CA CA2440293A patent/CA2440293C/en not_active Expired - Fee Related
- 2002-03-15 JP JP2003518456A patent/JP2004537576A/ja active Pending
- 2002-03-15 NZ NZ528321A patent/NZ528321A/en not_active IP Right Cessation
- 2002-03-15 DK DK02721413.9T patent/DK1372682T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ528321A (en) | 2006-09-29 |
| WO2003013442A2 (en) | 2003-02-20 |
| JP2004537576A (ja) | 2004-12-16 |
| ATE555807T1 (de) | 2012-05-15 |
| EP1372682B1 (en) | 2012-05-02 |
| CA2440293C (en) | 2012-01-24 |
| EP1372682A2 (en) | 2004-01-02 |
| WO2003013442A3 (en) | 2003-05-30 |
| EP1372682A4 (en) | 2005-10-19 |
| ES2387910T3 (es) | 2012-10-03 |
| CA2440293A1 (en) | 2003-02-20 |
| PT1372682E (pt) | 2012-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE555807T1 (de) | Catechine zur behandlung der fibrillogenese bei alzheimer-krankheit, parkinson-krankheit, systemischer aa-amyloidosis und anderer amyloid- störungen | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| NO20100264L (no) | Forhindring og behandling av amyloidogen sykdom | |
| DK1014996T3 (da) | Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser | |
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| BRPI0011867B8 (pt) | preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma | |
| NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| DE60228857D1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| EA200101250A1 (ru) | Предупреждение и терапия амилоидогенного заболевания | |
| NO20032111L (no) | Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter | |
| NO990595L (no) | Anvendelse av chelateringsmiddelet clikinol ved fremstilling av en farmas°ytisk sammensetning for behandling av alzheimers sykdom | |
| ATE529417T1 (de) | 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält | |
| WO2002076381A3 (en) | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases | |
| DE60138189D1 (de) | Eine neue verwendung von deferiprone | |
| ATE313334T1 (de) | Behandlung von tumoren mit photodynamischer therapie | |
| NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
| ATE99290T1 (de) | Substituierte 4-amino-2-butinyl-harnstoffe und - thioharnstoffe sowie deren derivate als zentral wirkende muscarinische mittel. | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
| DK0786998T3 (da) | Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom | |
| DK1492539T3 (da) | Statin-terapi til forögelse af kognitiv funktion | |
| MA26796A1 (fr) | Derive d'aminotetraline pour la therapie des maladies cardiovasculaires. | |
| DK0642338T3 (da) | Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom |